What are the Historical Developments and Current Growth Metrics of the Generative Artificial Intelligence (AI) In Drug Discovery Market?
The generative artificial intelligence (ai) in drug discovery market has seen considerable growth due to a variety of factors.
• The generative artificial intelligence (AI) in drug discovery market has seen rapid growth in recent years. It will rise from $0.19 billion in 2024 to $0.25 billion in 2025, at a compound annual growth rate (CAGR) of 30.9%.
The growth is attributed to the rise in chronic diseases, advancements in drug discovery and clinical trials, support for AI in healthcare and drug development, growing biotech industries, and increasing government support.
What is the Forecasted Market Size and CAGR for the Generative Artificial Intelligence (AI) In Drug Discovery Market?
The generative artificial intelligence (ai) in drug discovery market is expected to maintain its strong growth trajectory in upcoming years.
• The generative artificial intelligence (AI) in drug discovery market is anticipated to see rapid growth, reaching $0.74 billion by 2029, with a CAGR of 30.6%.
The growth is driven by the demand for cost-effective drug discovery processes, the adoption of generative AI, increased collaboration among market players, rising computational power, integration of generative AI with emerging technologies, and faster drug development timelines. Trends will include advancements in technology, the integration of generative AI with experimental biology, high-throughput screening for drug discovery, development of AI-driven drug repurposing platforms, and greater use of cloud-based AI solutions for collaborative drug discovery.
What Key Factors and Trends Are Driving The Growth Generative Artificial Intelligence (AI) In Drug Discovery Market?
The increase in clinical trials is projected to stimulate the growth of generative AI in the drug discovery market. Clinical trials involve testing new medical treatments or procedures on human volunteers to assess their safety and effectiveness. The rise in clinical trials is due to advancements in medical research, increased disease prevalence, regulatory changes, globalization of research, patient advocacy, and technological advancements. The data collected from these trials enhances generative AI models, speeding up drug discovery by predicting compound interactions and designing new treatments. This process improves personalized medicine, treatment efficacy, and patient outcomes. As of 2023, ClinicalTrials.gov reported 477,234 clinical trials globally, an increase from 437,512 in 2022, further driving the growth of generative AI in drug discovery.
What Are The Market Segments In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization
Pre-Book The Generative Artificial Intelligence (AI) In Drug Discovery Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Generative Artificial Intelligence (AI) In Drug Discovery Market?
Major companies in the generative AI in drug discovery market are developing advanced AI-powered tools to speed up the drug discovery process. These tools use predictive analytics and machine learning to optimize drug design, clinical trials, target identification, and compound screening. For example, in May 2023, Google Cloud, a US-based cloud computing service, launched two AI-driven solutions: the Target and Lead Identification Suite and the Multiomics Suite. These solutions help researchers analyze protein structures and genomic data more quickly, facilitating the development of personalized treatments and advancing drug discovery in biotech and pharmaceutical sectors.
Who Are the Key Players In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are:
• Bayer AG
• NVIDIA Corporation
• Merck KGaA
• IBM Research
• Schrödinger Inc.
• Valo Health
• BenevolentAI
• XtalPi Inc.
• Insilico Medicine Inc.
• Recursion Pharmaceuticals Inc.
• Exscientia
• Atomwise Inc.
• InveniAI LLC
• Healx
• Aitia
• Cloud Pharmaceuticals Inc.
• Optibrium
• Aiforia
• BioSymetrics Inc.
• Collaborations Pharmaceuticals Inc.
• MAbSilico
• Reverie Labs
• Standigm Inc.
• DeepMatter Group Limited
• Variational AI Inc
What Are The Regional Insights Into The Generative Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
